Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]:
SEC Accession No. 0001193125-26-092567
Filing Date
2026-03-05
Accepted
2026-03-05 07:31:11
Documents
76
Period of Report
2025-12-31

Document Format Files

Seq Description Document Type Size
1 10-K kura-20251231.htm   iXBRL 10-K 3793279
2 EX-10.11 kura-ex10_11.htm EX-10.11 26469
3 EX-23.1 kura-ex23_1.htm EX-23.1 7194
4 EX-31.1 kura-ex31_1.htm EX-31.1 17117
5 EX-32.1 kura-ex32_1.htm EX-32.1 10125
6 GRAPHIC img157892327_0.jpg GRAPHIC 1610653
  Complete submission text file 0001193125-26-092567.txt   17551883

Data Files

Seq Description Document Type Size
7 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT kura-20251231.xsd EX-101.SCH 1807306
79 EXTRACTED XBRL INSTANCE DOCUMENT kura-20251231_htm.xml XML 2475170
Mailing Address 4930 DIRECTORS PLACE, SUITE 500 SAN DIEGO CA 92121
Business Address 4930 DIRECTORS PLACE, SUITE 500 SAN DIEGO CA 92121 (858) 500-8800
Kura Oncology, Inc. (Filer) CIK: 0001422143 (see all company filings)

EIN.: 611547851 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-K | Act: 34 | File No.: 001-37620 | Film No.: 26724204
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)